A Study of Neoadjuvant TCHpy（Pyrotinib ，Trastuzumab，Carboplatin and Paclitaxel）for ER+/HER2+ Breast Cancer
This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.
Breast Cancer|Neoadjuvant
DRUG: pyrotinib,Trastuzumab，carboplatin，Albumin paclitaxel
total Pathological Complete Response(tPCR), 2 years
breast Pathological Complete Response(bPCR), 2 years|overall response rate(ORR), 2 years|event-free survival(EFS), 5 years
This study is a multicenter, single-arm, prospective, open clinical study to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, albumin paclitaxel, and carboplatin in neoadjuvant therapy for ER+/HER2+ early or locally advanced breast cancer.